SCHEMBL8962237

SCHEMBL8962237

CC(C)(C)CNC(=O)C(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.38
HDAC6 Q9UBN7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA7 P43166 1/20 0.36
CA14 Q9ULX7 1/20 0.36
PREP P48147 1/20 0.36
FAP Q12884 1/20 0.36
BCHE P06276 1/20 0.34
CACNA1H O95180 1/20 0.33
DPP4 P27487 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
MAPT P10636 2/20 0.32
KDM4E B2RXH2 2/20 0.32
CYP1A2 P05177 2/20 0.31
PGK1 P00558 1/20 0.31
PGK2 P07205 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PKM P14618 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24574899 0.83 SMN1; SMN2 (0.45) POLBHDAC6L3MBTL1CA1CA2
SCHEMBL21936665 0.82 SMN1; SMN2 (0.37) POLBHDAC6L3MBTL1CA1CA2
SCHEMBL21789486 0.82 SMN1; SMN2 (0.31) POLBSMN1; SMN2HSD17B10
SCHEMBL12920690 0.81 CNR2 (0.38) POLBHDAC6L3MBTL1CA1CA2
SCHEMBL17208224 0.80 POLB (0.34) POLBHDAC6L3MBTL1CA1CA2
SCHEMBL23612789 0.79 POLB (0.36) POLBHDAC6L3MBTL1CA1CA2
SCHEMBL21666589 0.79 BCHE (0.33) BCHE
SCHEMBL23612817 0.79 PGK1 (0.38) POLBCA2CA7CA14BCHE
SCHEMBL24263329 0.79 POLB (0.36) POLBHDAC6L3MBTL1CA1CA2
SCHEMBL18998493 0.79 PGK1 (0.42) POLBHDAC6L3MBTL1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113196536-B Use of solid electrolyte phase interface (SEI) on the anode of fluoride ion/shuttle batteries 本田技研工业株式会社 2025-02-11 CN disclosed
US-20240207423-A1 PROGAMMABLE POLYMERIC DRUGS SONY GROUP CORP (JP) 2024-06-27 US disclosed
US-11874280-B2 Use of divalent metals for enhancement of fluorescent signals Sony Group Corporation (JP) 2024-01-16 US disclosed
US-11830983-B2 Non-aqueous fluoride salts, solutions, and their uses CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-11-28 US disclosed
US-11830983-B2 Non-aqueous fluoride salts, solutions, and their uses CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-11-28 US disclosed
US-11830983-B2 Non-aqueous fluoride salts, solutions, and their uses CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2023-11-28 US disclosed
US-20230365609-A1 HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS GLYCOMIMETICS, INC. (US) 2023-11-16 US disclosed
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-11-09 US disclosed
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS ACHILLION PHARMACEUTICALS, INC. 2023-11-09 US disclosed
US-20230348450-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 US disclosed
US-20110077237-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-20100216714-A1 NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF JAMES KENNETH D 2010-08-26 US disclosed
US-20100028299-A1 Methods and compositions of treating a flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2010-02-04 US disclosed
US-20100028299-A1 Methods and compositions of treating a flaviviridae family viral infection THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2010-02-04 US disclosed
US-7648962-B2 which retain activity for stimulating cyclic guanosine monophosphate production and binding to natriuretic peptide receptor type A; improved bioavailability and half-life in circulation; for treatment of congestive heart failure BIOCON LIMITED (IN) 2010-01-19 US disclosed
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same SIGNUM BIOSCIENCES, INC. 2009-10-22 US disclosed
US-20090124602-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 2009-05-14 US disclosed
US-20080207505-A1 Bna Conjugates and Methods of Use JAMES KENNETH D 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264496-A1 Compounds, Compositions and Methods for Making the Same PPP2CA, PPP4C, PPP6C POLB 608/4885HDAC6 325/4885L3MBTL1 2966/4885
US-11830983-B2 Non-aqueous fluoride salts, solutions, and their uses NHERF1, BTF3, CACNA1F POLB 2265/4885HDAC6 4373/4885L3MBTL1 3378/4885
US-20080207505-A1 Bna Conjugates and Methods of Use NPR1, NPPA, NPR3 POLB 4596/4885HDAC6 3578/4885L3MBTL1 2575/4885
US-20090124602-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 POLB 1396/4885HDAC6 870/4885L3MBTL1 2582/4885
US-20100216714-A1 NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF NPR1, NPPA, NPR3 POLB 4773/4885HDAC6 3480/4885L3MBTL1 2591/4885
US-20230357199-A1 ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS CFD, TFPI, CFH POLB 3304/4885HDAC6 2840/4885L3MBTL1 4812/4885
US-20230348450-A1 CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, PGM2 POLB 150/4885HDAC6 3418/4885L3MBTL1 828/4885
US-20240207423-A1 PROGAMMABLE POLYMERIC DRUGS OPRM1, CHRM1, TUBB3 POLB 2043/4885HDAC6 800/4885L3MBTL1 444/4885
US-20110077237-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 POLB 1396/4885HDAC6 870/4885L3MBTL1 2582/4885
US-20230365609-A1 HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS SELE, SELP, SELPLG POLB 3988/4885HDAC6 1285/4885L3MBTL1 1898/4885
US-20100028299-A1 Methods and compositions of treating a flaviviridae family viral infection EIF2AK2, NSUN3, NSUN2 POLB 582/4885HDAC6 362/4885L3MBTL1 389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.